0 Membres et 1 Invité sur ce sujet
Grégoire Courtine : "Cette repousse des nerfs chez les rats ouvre des pistes thérapeutiques pour tester ce type d'intervention sur l'homme"
oui !! ça se rapproche, pouvoir se lever serait donc un rêve abordable dans un avenir trés proche
je te dis pas la bringue gillou mdr !
Regardez ce webdocumentaire en 3 épisodes, où plusieurs vidéos expliquent les recherches de l'équipe Suisse du Pr Courtine qui ont réussi à faire remarcher et même courir des rats paralysés. :arrow: http://www.project-rewalk.com/#/fr/homeL'association ALARME a soutenu cette équipe à hauteur de 16 000 € en 2012, et je pense doubler ce soutien en 2013 !(merci Marc pour le lien)
17-Fév-2013 Marcher de nouveau après une lésion médullaireDans le laboratoire, les rats avec une lésion sévère de la moelle épinière apprennent à marcher et courir de nouveau. En Juin dernier, dans la revue Science, Grégoire Courtine, de l'École Polytechnique Fédérale de Lausanne (EPFL), a rapporté que des rats dans son laboratoire n'ont pas seulement recommencer à marcher volontairement, mais aussi à courir, monter les escaliers, et éviter les obstacles après quelques semaines de réadaptation neurologique avec une combinaison de stimulation électrique-chimique et d'un harnais robotique.Lors de la réunion annuelle 2013 de l'American Association for the Advancement of Science (AAAS), à Boston, Grégoire Courtine a décrit en détail cette recherche et les prochaines étapes en vue d'essais cliniques prévus en Suisse. Courtine est le président de l'International Paraplegic Foundation (IRP) à l'EPFL. Il a décrit la technologie des neuroprothèses développée dans son laboratoire, qui visent à rétablir le contrôle volontaire de la locomotion après une lésion sévère de la moelle épinière. Courtine espère commencer les essais cliniques chez des patients humains dans les deux prochaines années. À l'AAAS, il a présenté le projet européen NeuWalk ( www.neuwalk.com ) de 9 millions d'euros, un effort dédié au transfert de technologie des rats aux humains avec des lésions de la moelle épinière à travers le développement de systèmes de neuroprothèses efficaces pour la réhabilitation. La première phase d'études cliniques sera effectuée à l'hôpital de l'Université de Lausanne (CHUV), qui a développé une grande expertise dans la stimulation électrique-chimique de la moelle épinière humaine. La deuxième phase aura lieu au nouveau pôle académique prévu de EPFL en Valais, en Suisse, qui sera inauguré en 2015. Ce centre de santé et de biotechnologie en Valais mettra l'accent sur de nouveaux traitements et de réadaptation pour les personnes ayant un handicap physique. Ce programme de recherche a le potentiel de développer des paradigmes de traitement efficaces pour réhabiliter les individus avec une lésion grave de la moelle épinière, pour qui les traitements actuels de réadaptation ne permettent pas de restaurer la capacité de se tenir debout ou de marcher.=========================== :arrow: TEXTE ORIGINAL EN ANGLAIS ===========================Public release date: 17-Feb-2013Walking again after spinal injuryIn the lab, rats with severe spinal cord injury are learning to walk—and run—again. Last June in the journal Science, Grégoire Courtine, of the École Polytechnique Fédérale de Lausanne (EPFL), reported that rats in his lab are not only voluntarily initiating a walking gait, but they were sprinting, climbing up stairs, and avoiding obstacles after a couple of weeks of neurorehabilitation with a combination of a robotic harness and electricalchemical stimulation.Now, at the 2013 Annual Meeting of the American Association for the Advancement of Science (AAAS) in Boston, Courtine describes this research in detail and the next steps towards clinical trials to be done in Switzerland. Courtine holds the International Paraplegic Foundation (IRP) Chair in Spinal Cord Repair at EPFL. At AAAS, in a symposium titled, “Engineering the Nervous System: Solutions to Restore Sight, Hearing, and Mobility,” he outlines the range of neuroprosthetic technologies developed in his lab, which aim to restore voluntary control of locomotion after severe spinal cord injury. He explains how he and his colleagues are interfacing the central nervous system with stretchable spinal electrode arrays controlled with smart stimulation algorithms – combined with novel robotic rehabilitation – and shows videos of completely paralyzed rats voluntarily moving after only weeks of treatment.Courtine expects to begin clinical trials in human patients within the next two years. At AAAS, he presents the 9 million euro European project NeuWalk (http://www.neuwalk.eu), an effort dedicated to the transfer of technology from rats over to humans with spinal cord damage through development of effective neuroprosthetic systems for rehabilitation. The first phase of clinical studies will be conducted at the Lausanne University Hospital (CHUV), which has developed extensive expertise in the electrical-chemical stimulation of the human spinal cord. The second phase will take place at the newly planned EPFL Valais Wallis academic cluster in Valais, Switzerland, to be inaugurated in 2015. This health and biotechnology center in Valais will focus on new treatments and rehabilitation for people with physical disabilities. This research program has the potential to develop effective treatment paradigms for rehabilitating individuals with severe spinal cord injury, for whom current rehabilitative treatments do not restore the ability to stand or walk.More information:Researcher Contact : Professor Grégoire Courtine International Paraplegic Foundation (IRP) Chair in Spinal Cord Repair gregoire.courtine@epfl.ch http://courtine-lab.epfl.chSource : http://www.eurekalert.org/pub_releases/2013-02/epfd-waa021113.php
Remarcher un jour: on avance pas à pasLes medias se font régulièrement l’écho d’avancées scientifiques qui permettraient aux paraplégiques de remarcher un jour. La Suisse est à la pointe dans certains de ces domaines de recherche. Mais ceux qui les mènent rappellent que les développements prennent beaucoup de temps.....
I sincerely thank you for believing in our research and its potential therapeutic outcome. The dedication necessary to orchestrate the research in my lab – in order to accelerate the translation of our findings in rats to a viable intervention for humans with spinal cord injury – prevents me from responding to your query in a fast and personal manner. Indeed, every week my lab receives numerous letters, emails and phone calls requesting information on our work or expressing the desire to enroll in a clinical trial. I nevertheless hope that this letter will help clarify the status of our efforts towards implementing clinical trials. At this stage, I can only emphasize that the strategy we are developing does not constitute a cure for spinal cord injury. In particular, a combination of our therapy with other available treatments, such as neuroregenerative interventions, will play a critical role to improve spinal cord function after near-complete, chronic injury. Currently, we have limited information on the ability of this treatment paradigm to improve motor function after other neurological disorders such as multiple sclerosis or ALS. We are investigating the impact of electrical spinal cord stimulation in other neurological conditions, but it is premature to draw conclusions.Tremendous efforts are being made to further optimize and validate the technology necessary to translate our approach into a viable clinical application for humans. We are doing this in collaboration with a dedicated and expert consortium of European laboratories (www.neuwalk.eu). Over the past year, we achieved a few milestones for humans. These include the development of a robotic interface for training human patients in natural conditions, and the preliminary design of electrical spinal cord stimulators that will allow stimulation of the spinal cord similar to the paradigms developed for rodents. These new technologies establish the setting for implementation of afirst clinical study, to be done in collaboration with the University Hospital (CHUV) in Lausanne. Prof. Curt and Prof. Schurch, both with over 25 years of experience in spinal cord injury medicine, will supervise the selection of patients and the functional evaluations. Prof. Bloch, head of functional neurosurgery at the CHUV, will be in charge of all the surgical aspects of the study. This first study will involve 8 paraplegic candidates with residual connectivity across the injury, which will be verified by the presence of voluntary movement in the legs despite being unable to walk. Ideally, these individuals will live close to Lausanne in order to allow extensive testing and rehabilitation for 6 to 9 months.We are still waiting for approval of the ethical commission to initiate the clinical trial. Consequently, we cannot legally start enrolling candidates in this study. If you wish, your email information can be stored in a large database of interested individuals. Upon release of official authorization for the launch of a clinical trial, you will be directly informed via an email diffusion list.In parallel, we are conducting extensive testing in macaques to identify the relevant pharmacological agents to promote locomotion in a species closer to humans. Our aim is to ensure the safe and efficient translation of our findings in rodents to humans. Evaluation of the combination of electrical spinal cord stimulation and pharmacological agents will take several years. This long period is due to the need for pharmacological development and the time required to collect sufficient information on safety and to ensure the absence of neurotoxicity. A comprehensive therapeutic strategy will be implemented in a second phase through a clinical trial conducted with newly injured individuals in our paraplegic center, planned to open in Sion in 2017 (http://actu.epfl.ch/news/epfl-and-the-state-of-valais-have-signed-a-partner/).If you are seeking more information, you may go to www.project-rewalk.com. This web documentary relates the scientific and human journey of my laboratory. New episodes will complement the documentary in the near future, as new experimental and clinical progresses are achieved.Please understand that this endeavor is not merely a scientific opportunity for me. I cannot promise you that our therapy will bring functional improvement for spinal cord injured people; but I promise you that my team and I will do the impossible to find out.As our emblematic patient David says in the Web Documentary: “Let’s hope, and go for it”.Sincerely, Dr. Grégoire Courtine---------------------------------------------------------------------------------------Prof. Dr. Grégoire CourtineInternational Paraplegic Foundation Chair in Spinal Cord Repair Center for Neuroprosthetics and Brain Mind InstituteSchool of Life Sciences Swiss Federal Institute of Technology (EPFL)1015 Lausanne, Switzerland EPFL SV UPCOURTINE - station 19Office: SV - 2808 Tel: +41 21 69 38343Cell: +41 79 564 74 96Fax: +41 21 693 07 40E-mail: gregoire.courtine@epfl.chWebsite: http://courtine-lab.epfl.ch/Visit the Web Documentary on G-lab: www.project-rewalk.com---------------------------------------------------------------------------------------Executive Assistant: Kim-Yen NguyenE-mail: kim-yen.nguyen@epfl.chTel: +41 21 69 30762
Auteur
Sujet: Neurostimulation implantée - Pr. Grégoire Courtine (EPFL - Suisse) (Lu 89249 fois)
